NNMT inhibitor (small molecule, NOT a peptide)
A small quinolinium molecule studied for fat/metabolic research; grouped with peptides commercially but chemically an enzyme inhibitor.
| Class / type | NNMT inhibitor (small molecule, NOT a peptide) |
|---|---|
| Category | Metabolic & Weight |
| Status (Jul 2026) | Research use only |
Inhibits NNMT, slowing conversion of nicotinamide to 1-methylnicotinamide; may preserve NAD+ salvage and alter adipose energy metabolism.
Preclinical obesity, metabolic dysfunction, NAD+ metabolism research.
Preclinical effects on fat-cell metabolism and NAD+; reported oral availability and NNMT selectivity.
No human trials or established safety; human dosing/effects unknown; gray-market purity unverified.
Oral (non-injectable) format; 'novel mechanism' appeal of boosting NAD+ / targeting fat differently from GLP-1s.
NOT FDA-approved; no approved indication. Sold strictly as a research chemical.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.